Topic

Cigna

A collection of 1059 issues

How to Get Uplizna (Inebilizumab) Covered by Cigna in Pennsylvania: Complete Guide to Prior Authorization, Appeals, and Cost Savings

Answer Box: Getting Uplizna Covered by Cigna in Pennsylvania Uplizna (inebilizumab) requires prior authorization from Cigna and is typically covered on Tier 5 (specialty) with mandatory use of Accredo specialty pharmacy. The fastest path to approval: 1) Have your neurologist submit a comprehensive PA request documenting AQP4-positive NMOSD diagnosis and
6 min read

Getting Therakos CELLEX Photopheresis Covered by Cigna in Pennsylvania: Complete Guide to Prior Authorization and Appeals

Quick Answer: Getting Therakos CELLEX Covered by Cigna in Pennsylvania Yes, Cigna covers Therakos CELLEX photopheresis for FDA-approved indications like cutaneous T-cell lymphoma (CTCL) and steroid-refractory graft-versus-host disease (GVHD), but prior authorization is required. Submit your PA through Cigna's provider portal with detailed documentation of failed prior therapies
6 min read

How to Get Zolgensma (onasemnogene abeparvovec) Covered by Cigna in Ohio: Complete Prior Authorization Guide with Appeal Scripts

Answer Box: Getting Zolgensma Covered by Cigna in Ohio Cigna requires prior authorization for Zolgensma (onasemnogene abeparvovec) using their Gene Therapy PA form, with extensive clinical documentation including genetic testing, baseline labs, and age verification. Submit via fax to 833-910-1625 with all supporting documents. If denied, Ohio residents have internal
6 min read

How to Get Duopa (Carbidopa/Levodopa Enteral) Covered by Cigna in California: Prior Authorization Guide and Appeals Process

Answer Box: Cigna covers Duopa (carbidopa/levodopa enteral) with prior authorization for advanced Parkinson's disease patients experiencing motor fluctuations despite optimized oral therapy. Three steps to approval: 1) Your neurologist submits PA documentation showing failed oral carbidopa/levodopa trials and ≥3 hours daily OFF time, 2) Cigna reviews
6 min read